$81.57
0.72% day before yesterday
Nasdaq, Sep 06, 10:05 pm CET
ISIN
US4364401012
Symbol
HOLX

Hologic Stock price

$81.57
-0.88 1.07% 1M
+6.37 8.47% 6M
+10.12 14.16% YTD
+7.47 10.08% 1Y
+1.32 1.64% 3Y
+31.86 64.09% 5Y
+56.04 219.51% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.58 0.72%
ISIN
US4364401012
Symbol
HOLX
Sector

Key metrics

Market capitalization $18.95b
Enterprise Value $19.07b
P/E (TTM) P/E ratio 27.83
EV/FCF (TTM) EV/FCF 18.61
EV/Sales (TTM) EV/Sales 4.78
P/S ratio (TTM) P/S ratio 4.75
P/B ratio (TTM) P/B ratio 3.82
Revenue growth (TTM) Revenue growth -1.26%
Revenue (TTM) Revenue $3.99b
EBIT (operating result TTM) EBIT $922.70m
Free Cash Flow (TTM) Free Cash Flow $1.02b
Cash position $2.44b
EPS (TTM) EPS $2.93
P/E forward 23.83
P/S forward 4.71
EV/Sales forward 4.74
Short interest 3.35%
Show more

Is Hologic a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Hologic Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Hologic forecast:

11x Buy
52%
9x Hold
43%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a Hologic forecast:

Buy
52%
Hold
43%
Sell
5%

Financial data from Hologic

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,988 3,988
1% 1%
100%
- Direct Costs 1,809 1,809
1% 1%
45%
2,179 2,179
3% 3%
55%
- Selling and Administrative Expenses 668 668
2% 2%
17%
- Research and Development Expense 278 278
6% 6%
7%
1,233 1,233
4% 4%
31%
- Depreciation and Amortization 310 310
13% 13%
8%
EBIT (Operating Income) EBIT 923 923
1% 1%
23%
Net Profit 702 702
45% 45%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Hologic directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hologic Stock News

Neutral
Business Wire
9 days ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference.
Neutral
Seeking Alpha
about one month ago
Hologic, Inc. (NASDAQ:HOLX ) Q3 2024 Earnings Conference Call July 29, 2024 4:30 AM ET Company Participants Ryan Simon - VP, IR Stephen MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Vijay Kumar - Evercore Anthony Petrone - Mizuho Securities Michael...
Positive
Reuters
about one month ago
Medical technology company Hologic reported a higher third-quarter profit on Monday, driven by strong demand for its diagnostics and breast health products, but forecast revenue for the current quarter that fell short of Wall Street estimates.
More Hologic News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.

Head office United States
CEO Stephen MacMillan
Employees 6,990
Founded 1985
Website www.hologic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today